Gemcitabine + nab-paclitaxel (MPACT)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-GEMCITABINE DRUG-NAB-PACLITAXEL |
|---|
| ID | REG-GEM-NAB-PAC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Notes
MPACT trial: gem-nab-pac vs gemcitabine in metastatic PDAC PS 0-2 — mOS 8.5 vs 6.7 mo, ORR 23 vs 7%. Better-tolerated alternative to FOLFIRINOX for ECOG 1-2 / older / borderline-fit patients. Less cumulative neuropathy + neutropenia than FOLFIRINOX but more day-15 cytopenia.
Used By
Indication
IND-PDAC-METASTATIC-1L-GEM-NAB-PAC- IND-PDAC-METASTATIC-1L-GEM-NAB-PAC
Regimen
REG-NALIRIFOX- NALIRIFOX